In conclusion, our results indicate that although most of the GPV found in this study were in the BRCA1/2 genes (9.6%), women who fulfill the clinical criteria for HBOC may benefit from multigene panel testing, because the panel allows to identify GPV in relevant BC predisposing genes (7.2%), including those who change the clinical management. Here, BRCA1 is linked to breast cancer.